Zentalis Pharmaceuticals Inc

Insider option buys at Zentalis signal executive confidence in a hopeful Azenosertib launch—boosting momentum but flagging the risk of negative earnings and milestone‑dependent valuation.

Insider buying at Zentalis signals confidence in its oncology pipeline, especially Azenosertib—may lift stock beyond 52‑week highs amid volatile pricing.